Detection of cancer at an early stage when it is still localized improves patient response to medical interventions for most cancer types. The success of screening tools such as cervical cytology to reduce mortality has spurred significant interest in new methods for early detection (for example, using non-invasive blood-based or biofluid-based biomarkers). Yet biomarkers shed from early lesions are limited by fundamental biological and mass transport barriers — such as short circulation times and blood dilution — that limit early detection. To address this issue, synthetic biomarkers are being developed. These represent an emerging class of diagnostics that deploy bioengineered sensors inside the body to query early-stage tumours and amplify disease signals to levels that could potentially exceed those of shed biomarkers. These strategies leverage design principles and advances from chemistry, synthetic biology and cell engineering. In this Review, we discuss the rationale for development of biofluid-based synthetic biomarkers. We examine how these strategies harness dysregulated features of tumours to amplify detection signals, use tumour-selective activation to increase specificity and leverage natural processing of bodily fluids (for example, blood, urine and proximal fluids) for easy detection. Finally, we highlight the challenges that exist for preclinical development and clinical translation of synthetic biomarker diagnostics.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7–30 (2020).
National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365, 395–409 (2011).
Ru Zhao, Y. et al. NELSON lung cancer screening study. Cancer Imaging 11 Spec. No. A, S79–S84 (2011).
Siu, A. L. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 164, 279–296 (2016).
Bibbins-Domingo, K. et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA 315, 2564–2575 (2016).
Curry, S. J. et al. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA 320, 674–686 (2018).
Moyer, V. A. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 160, 330–338 (2014).
Pinsky, P. F., Prorok, P. C. & Kramer, B. S. Prostate cancer screening - a perspective on the current state of the evidence. N. Engl. J. Med. 376, 1285–1289 (2017).
Cohen, J. D. et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359, 926–930 (2018).
Au, S. H. et al. Clusters of circulating tumor cells: a biophysical and technological perspective. Curr. Opin. Biomed. Eng. 3, 13–19 (2017).
Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra224 (2014).
Maheswaran, S. et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359, 366–377 (2008).
Dawson, S. J. et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368, 1199–1209 (2013).
Lennon, A. M. et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science 369, eabb9601 (2020).
De Rubis, G., Rajeev Krishnan, S. & Bebawy, M. Liquid biopsies in cancer diagnosis, monitoring, and prognosis. Trends Pharmacol. Sci. 40, 172–186 (2019).
Sokoll, L. J. et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol. Biomarkers Prev. 19, 1193–1200 (2010).
Karlsen, M. A. et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol. Oncol. 127, 379–383 (2012).
Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498 (2014).
Prensner, J. R., Rubin, M. A., Wei, J. T. & Chinnaiyan, A. M. Beyond PSA: the next generation of prostate cancer biomarkers. Sci. Transl. Med. 4, 127rv123 (2012).
Hammarström, S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin. Cancer Biol. 9, 67–81 (1999).
Imperiale, T. F., Ransohoff, D. F. & Itzkowitz, S. H. Multitarget stool DNA testing for colorectal-cancer screening. N. Engl. J. Med. 371, 187–188 (2014).
Serganova, I. & Blasberg, R. G. Molecular imaging with reporter genes: has its promise been delivered? J. Nucl. Med. 60, 1665–1681 (2019).
Gilad, A. A. & Shapiro, M. G. Molecular imaging in synthetic biology, and synthetic biology in molecular imaging. Mol. Imaging Biol. 19, 373–378 (2017).
Condeelis, J. & Weissleder, R. In vivo imaging in cancer. Cold Spring Harb. Perspect. Biol. 2, a003848 (2010).
Kwong, G. A. et al. Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease. Nat. Biotechnol. 31, 63–70 (2013). This study first describes the design of protease-activated synthetic biomarkers for non-invasive detection of colorectal cancer from urine in a mouse model.
Abbosh, C. et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545, 446–451 (2017).
Heitzer, E., Haque, I. S., Roberts, C. E. S. & Speicher, M. R. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat. Rev. Genet. 20, 71–88 (2019). This comprehensive review highlights the opportunities as well as the many challenges that must be overcome before liquid biopsies can be widely used for cancer detection.
Fleischhacker, M. & Schmidt, B. Circulating nucleic acids (CNAs) and cancer — a survey. Biochim. Biophys. Acta Rev. Cancer 1775, 181–232 (2007).
Diehl, F. et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 14, 985–990 (2008).
Erdi, Y. E. Limits of tumor detectability in nuclear medicine and PET. Mol. Imaging Radionucl. Ther. 21, 23–28 (2012).
Lutz, A. M., Willmann, J. K., Cochran, F. V., Ray, P. & Gambhir, S. S. Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes. PLoS Med. 5, e170 (2008).
Hori, S. S. & Gambhir, S. S. Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations. Sci. Transl. Med. 3, 109ra116 (2011). In this study, the authors develop a mathematical model to determine how early a clinical blood biomarker can be used to detect cancer.
Hori, S. S., Lutz, A. M., Paulmurugan, R. & Gambhir, S. S. A model-based personalized cancer screening strategy for detecting early-stage tumors using blood-borne biomarkers. Cancer Res. 77, 2570–2584 (2017).
Machiraju, G. B., Mallick, P. & Frieboes, H. B. Multicompartment modeling of protein shedding kinetics during vascularized tumor growth. Sci. Rep. 10, 16709 (2020).
Birkbak, N. J. & McGranahan, N. Cancer genome evolutionary trajectories in metastasis. Cancer Cell 37, 8–19 (2020).
Lambert, A. W., Pattabiraman, D. R. & Weinberg, R. A. Emerging biological principles of metastasis. Cell 168, 670–691 (2017).
Massague, J. & Obenauf, A. C. Metastatic colonization by circulating tumour cells. Nature 529, 298–306 (2016).
Turajlic, S. & Swanton, C. Metastasis as an evolutionary process. Science 352, 169–175 (2016).
Labidi-Galy, S. I. et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat. Commun. 8, 1093 (2017).
Conner, J. R. et al. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol. Oncol. 132, 280–286 (2014).
Lopez-Giacoman, S. & Madero, M. Biomarkers in chronic kidney disease, from kidney function to kidney damage. World J. Nephrol. 4, 57–73 (2015).
Ishizawa, T. et al. Real-time identification of liver cancers by using indocyanine green fluorescent imaging. Cancer 115, 2491–2504 (2009).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Kwon, E. J., Dudani, J. S. & Bhatia, S. N. Ultrasensitive tumour-penetrating nanosensors of protease activity. Nat. Biomed. Eng. 1, 0054 (2017).
Kessenbrock, K., Plaks, V. & Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52–67 (2010).
Ribatti, D., Nico, B., Crivellato, E., Roccaro, A. M. & Vacca, A. The history of the angiogenic switch concept. Leukemia 21, 44–52 (2007).
Dudani, J. S., Ibrahim, M., Kirkpatrick, J., Warren, A. D. & Bhatia, S. N. Classification of prostate cancer using a protease activity nanosensor library. Proc. Natl Acad. Sci. USA 115, 8954–8959 (2018).
Kirkpatrick, J. D. et al. Urinary detection of lung cancer in mice via noninvasive pulmonary protease profiling. Sci. Transl. Med. 12, eaaw0262 (2020). This study demonstrates the use of a 14-plex library of synthetic biomarkers for early detection of lung cancer in genetically engineered mouse models.
Mac, Q. D. et al. Non-invasive early detection of acute transplant rejection via nanosensors of granzyme B activity. Nat. Biomed. Eng. 3, 281–291 (2019).
Lin, K. Y., Kwong, G. A., Warren, A. D., Wood, D. K. & Bhatia, S. N. Nanoparticles that sense thrombin activity as synthetic urinary biomarkers of thrombosis. ACS Nano 7, 9001–9009 (2013).
Kwong, G. A. et al. Mathematical framework for activity-based cancer biomarkers. Proc. Natl Acad. Sci. USA 112, 12627–12632 (2015). This study develops a physiologically based pharmacokinetic model to predict the performance of protease-activated synthetic biomarkers for early cancer detection in humans.
Dudani, J. S., Warren, A. D. & Bhatia, S. N. Harnessing protease activity to improve cancer care. Annu. Rev. Canc Biol. 2, 353–376 (2018).
Soo Choi, H. et al. Renal clearance of quantum dots. Nat. Biotechnol. 25, 1165 (2007).
Dudani, J. S., Jain, P. K., Kwong, G. A., Stevens, K. R. & Bhatia, S. N. Photoactivated spatiotemporally-responsive nanosensors of in vivo protease activity. ACS Nano 9, 11708–11717 (2015).
Wittrup, K. D., Thurber, G. M., Schmidt, M. M. & Rhoden, J. J. Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol. 503, 255–268 (2012).
Mac, Q. D. et al. Activity-based urinary biomarkers of response and resistance to checkpoint blockade immunotherapy. bioRxiv https://doi.org/10.1101/2020.12.10.420265 (2021).
Hao, L., Zhao, R. T., Ngambenjawong, C., Fleming, H. E. & Bhatia, S. N. CRISPR-Cas-amplified urine biomarkers for multiplexed and portable cancer diagnostics. bioRxiv https://doi.org/10.1101/2020.06.17.157180 (2020).
Warren, A. D. et al. Disease detection by ultrasensitive quantification of microdosed synthetic urinary biomarkers. J. Am. Chem. Soc. 136, 13709–13714 (2014).
Warren, A. D., Kwong, G. A., Wood, D. K., Lin, K. Y. & Bhatia, S. N. Point-of-care diagnostics for noncommunicable diseases using synthetic urinary biomarkers and paper microfluidics. Proc. Natl Acad. Sci. USA 111, 3671–3676 (2014).
Chan, L. W. et al. Engineering synthetic breath biomarkers for respiratory disease. Nat. Nanotechnol. 15, 792–800 (2020).
Loynachan, C. N. et al. Renal clearable catalytic gold nanoclusters for in vivo disease monitoring. Nat. Nanotechnol. 14, 883–890 (2019).
Nishihara, T. et al. Beta-galactosidase-responsive synthetic biomarker for targeted tumor detection. Chem. Commun. 54, 11745–11748 (2018).
Nishihara, T. et al. Synthetic biomarker design by using analyte-responsive acetaminophen. Chembiochem 18, 910–913 (2017).
Fernandez-Garcia, J., Altea-Manzano, P., Pranzini, E. & Fendt, S. M. Stable isotopes for tracing mammalian-cell metabolism in vivo. Trends Biochem. Sci. 45, 185–201 (2020).
Perets, T. T. et al. Optimization of 13C-urea breath test threshold levels for the detection of Helicobacter pylori infection in a national referral laboratory. J. Clin. Lab. Anal. 33, e22674 (2019).
Gorowska-Kowolik, K., Chobot, A. & Kwiecien, J. 13C methacetin breath test for assessment of microsomal liver function: methodology and clinical application. Gastroenterol. Res. Pract. 2017, 7397840 (2017).
Hoteit, M. A. et al. Deterioration in liver function after liver-directed therapy for hepatocellular carcinoma measured by cholate clearance. GastroHep 2, 232–239 (2020).
Hanna, G. B., Boshier, P. R., Markar, S. R. & Romano, A. Accuracy and methodologic challenges of volatile organic compound-based exhaled breath tests for cancer diagnosis: a systematic review and meta-analysis. JAMA Oncol. 5, e182815 (2019).
Djago, F., Lange, J. & Poinot, P. Induced volatolomics of pathologies. Nat. Rev. Chem. 5, 183–196 (2021).
Lange, J. et al. Volatile organic compound based probe for induced volatolomics of cancers. Angew. Chem. Int. Ed. 58, 17563–17566 (2019). The authors of this study report the use of a deuterated metabolite that is released as a VOC in exhaled breath for cancer diagnosis in mice.
Bhang, H. E., Gabrielson, K. L., Laterra, J., Fisher, P. B. & Pomper, M. G. Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression. Nat. Med. 17, 123–129 (2011). In this report of a vector-based synthetic biomarker, the authors demonstrate the use of a tumour-specific promoter to drive the production of a reporter to image disseminated cancer in mouse models of melanoma and breast cancer.
Browne, A. W. et al. Cancer screening by systemic administration of a gene delivery vector encoding tumor-selective secretable biomarker expression. PLoS ONE 6, e19530 (2011).
Warram, J. M. et al. Systemic delivery of a breast cancer-detecting adenovirus using targeted microbubbles. Cancer Gene Ther. 19, 545–552 (2012).
Warram, J. M., Borovjagin, A. V. & Zinn, K. R. A genetic strategy for combined screening and localized imaging of breast cancer. Mol. Imaging Biol. 13, 452–461 (2011).
D’Souza, A. L. et al. A strategy for blood biomarker amplification and localization using ultrasound. Proc. Natl Acad. Sci. USA 106, 17152–17157 (2009).
Aalipour, A. et al. Engineered immune cells as highly sensitive cancer diagnostics. Nat. Biotechnol. 37, 531–539 (2019). This study describes engineered macrophages as immune cell sensors that detect cancer after infiltration by releasing a synthetic biomarker in response to metabolic polarization.
Ronald, J. A., Chuang, H.-Y., Dragulescu-Andrasi, A., Hori, S. S. & Gambhir, S. S. Detecting cancers through tumor-activatable minicircles that lead to a detectable blood biomarker. Proc. Natl Acad. Sci. USA 112, 3068–3073 (2015).
Niu, G. & Chen, X. Molecular imaging with activatable reporter systems. Theranostics 2, 413–423 (2012).
Montano-Samaniego, M., Bravo-Estupinan, D. M., Mendez-Guerrero, O., Alarcon-Hernandez, E. & Ibanez-Hernandez, M. Strategies for targeting gene therapy in cancer cells with tumor-specific promoters. Front. Oncol. 10, 605380 (2020).
Tannous, B. A. & Teng, J. Secreted blood reporters: insights and applications. Biotechnol. Adv. 29, 997–1003 (2011).
Chao, C. N. et al. Gene therapy for human lung adenocarcinoma using a suicide gene driven by a lung-specific promoter delivered by JC virus-like particles. PLoS ONE 11, e0157865 (2016).
Wu, C. et al. Combinatorial control of suicide gene expression by tissue-specific promoter and microRNA regulation for cancer therapy. Mol. Ther. 17, 2058–2066 (2009).
Jafri, M. A., Ansari, S. A., Alqahtani, M. H. & Shay, J. W. Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med. 8, 69 (2016).
Jiang, H. et al. Arginine deiminase expressed in vivo, driven by human telomerase reverse transcriptase promoter, displays high hepatoma targeting and oncolytic efficiency. Oncotarget 8, 37694–37704 (2017).
Kyo, S., Takakura, M., Fujiwara, T. & Inoue, M. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 99, 1528–1538 (2008).
Li, C. et al. MR molecular imaging of tumors based on an optimal hTERT promoter tyrosinase expression system. Oncotarget 7, 42474–42484 (2016).
Berger, J., Hauber, J., Hauber, R., Geiger, R. & Cullen, B. R. Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells. Gene 66, 1–10 (1988).
Bettan, M., Darteil, R. & Scherman, D. Secreted human placental alkaline phosphatase as a reporter gene for in vivo gene transfer. Anal. Biochem. 271, 187–189 (1999).
Bao, R., Selvakumaran, M. & Hamilton, T. C. Use of a surrogate marker (human secreted alkaline phosphatase) to monitor in vivo tumor growth and anticancer drug efficacy in ovarian cancer xenografts. Gynecol. Oncol. 78, 373–379 (2000).
Nilsson, E. E. et al. An in vivo mouse reporter gene (human secreted alkaline phosphatase) model to monitor ovarian tumor growth and response to therapeutics. Cancer Chemother. Pharmacol. 49, 93–100 (2002).
Richter, J. R., Mahoney, M., Warram, J. M., Samuel, S. & Zinn, K. R. A dual-reporter, diagnostic vector for prostate cancer detection and tumor imaging. Gene Ther. 21, 897–902 (2014).
Hiramatsu, N. et al. Alkaline phosphatase vs luciferase as secreted reporter molecules in vivo. Anal. Biochem. 339, 249–256 (2005).
Tannous, B. A. Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nat. Protoc. 4, 582–591 (2009).
Wurdinger, T. et al. A secreted luciferase for ex vivo monitoring of in vivo processes. Nat. Methods 5, 171–173 (2008).
Alessandrini, F., Ceresa, D., Appolloni, I., Marubbi, D. & Malatesta, P. Noninvasive monitoring of glioma growth in the mouse. J. Cancer 7, 1791–1797 (2016).
Chung, E. et al. Secreted Gaussia luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases. PLoS ONE 4, e8316 (2009).
Tseng, A. W., Akerstrom, V., Chen, C., Breslin, M. B. & Lan, M. S. Detection of neuroendocrine tumors using promoter-specific secreted Gaussia luciferase. Int. J. Oncol. 48, 173–180 (2016).
Liu, S. H. et al. BIRC5 is a target for molecular imaging and detection of human pancreatic cancer. Cancer Lett. 457, 10–19 (2019).
Fang, Y., Wolfson, B. & Godbey, W. T. Non-invasive detection of bladder cancer via expression-targeted gene delivery. J. Gene Med. 19, 366–375 (2017).
Almeida, A. M., Queiroz, J. A., Sousa, F. & Sousa, A. Minicircle DNA: the future for DNA-based vectors? Trends Biotechnol. 38, 1047–1051 (2020).
Oliveira, P. H. & Mairhofer, J. Marker-free plasmids for biotechnological applications - implications and perspectives. Trends Biotechnol. 31, 539–547 (2013).
Huyn, S. T. et al. A potent, imaging adenoviral vector driven by the cancer-selective mucin-1 promoter that targets breast cancer metastasis. Clin. Cancer Res. 15, 3126–3134 (2009).
Wang, T., Chen, Y. & Ronald, J. A. A novel approach for assessment of prostate cancer aggressiveness using survivin-driven tumour-activatable minicircles. Gene Ther. 26, 177–186 (2019).
Reagan, M. R. & Kaplan, D. L. Concise review: mesenchymal stem cell tumor-homing: detection methods in disease model systems. Stem Cell 29, 920–927 (2011).
Liu, L. et al. Exogenous marker-engineered mesenchymal stem cells detect cancer and metastases in a simple blood assay. Stem Cell Res. Ther. 6, 181 (2015).
Karp, J. M. & Leng Teo, G. S. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 4, 206–216 (2009).
Droujinine, I. A., Eckert, M. A. & Zhao, W. To grab the stroma by the horns: from biology to cancer therapy with mesenchymal stem cells. Oncotarget 4, 651–664 (2013).
Kouidhi, S., Noman, M. Z., Kieda, C., Elgaaied, A. B. & Chouaib, S. Intrinsic and tumor microenvironment-induced metabolism adaptations of T cells and impact on their differentiation and function. Front. Immunol. 7, 114 (2016).
Somasundaram, R. et al. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat. Commun. 8, 607 (2017).
Vitale, M., Cantoni, C., Pietra, G., Mingari, M. C. & Moretta, L. Effect of tumor cells and tumor microenvironment on NK-cell function. Eur. J. Immunol. 44, 1582–1592 (2014).
Smith, T. T. et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat. Nanotechnol. 12, 813–820 (2017).
Perez, C., Gruber, I. & Arber, C. Off-the-shelf allogeneic T cell therapies for cancer: opportunities and challenges using naturally occurring “universal” donor T cells. Front. Immunol. 11, 583716 (2020).
Forbes, N. S. Engineering the perfect (bacterial) cancer therapy. Nat. Rev. Cancer 10, 785–794 (2010).
Zheng, J. H. et al. Two-step enhanced cancer immunotherapy with engineered Salmonella Typhimurium secreting heterologous flagellin. Sci. Transl. Med. 9, eaak9537 (2017).
Jiang, S. N. et al. Inhibition of tumor growth and metastasis by a combination of Escherichia coli-mediated cytolytic therapy and radiotherapy. Mol. Ther. 18, 635–642 (2010).
Zhou, S., Gravekamp, C., Bermudes, D. & Liu, K. Tumour-targeting bacteria engineered to fight cancer. Nat. Rev. Cancer 18, 727–743 (2018).
Panteli, J. T., Van Dessel, N. & Forbes, N. S. Detection of tumors with fluoromarker-releasing bacteria. Int. J. Cancer 146, 137–149 (2020).
Panteli, J. T., Forkus, B. A., Van Dessel, N. & Forbes, N. S. Genetically modified bacteria as a tool to detect microscopic solid tumor masses with triggered release of a recombinant biomarker. Integr. Biol. 7, 423–434 (2015).
Danino, T. et al. Programmable probiotics for detection of cancer in urine. Sci. Transl. Med. 7, 289ra284–289ra284 (2015). The authors of this study engineer the probiotic E. coli Nissle to colonize and report on the presence of liver tumours in mice by producing a colorimetric readout in urine.
Slomovic, S., Pardee, K. & Collins, J. J. Synthetic biology devices for in vitro and in vivo diagnostics. Proc. Natl Acad. Sci. USA 112, 14429–14435 (2015).
Danino, T., Mondragon-Palomino, O., Tsimring, L. & Hasty, J. A synchronized quorum of genetic clocks. Nature 463, 326–330 (2010).
Prindle, A. et al. A sensing array of radically coupled genetic ‘biopixels’. Nature 481, 39–44 (2011).
Din, M. O. et al. Synchronized cycles of bacterial lysis for in vivo delivery. Nature 536, 81–85 (2016).
Chowdhury, S. et al. Programmable bacteria induce durable tumor regression and systemic antitumor immunity. Nat. Med. 25, 1057–1063 (2019).
Gurbatri, C. R. et al. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci. Transl. Med. 12, eaax0876 (2020).
Ho, C. L. et al. Engineered commensal microbes for diet-mediated colorectal-cancer chemoprevention. Nat. Biomed. Eng. 2, 27–37 (2018).
Brown, P. O. & Palmer, C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med. 6, e1000114 (2009).
Rakhit, C. P. et al. Early detection of pre-malignant lesions in a KRASG12D-driven mouse lung cancer model by monitoring circulating free DNA. Dis. Model Mech. 12, dmm036863 (2019).
Whitney, M. et al. Parallel in vivo and in vitro selection using phage display identifies protease-dependent tumor-targeting peptides. J. Biol. Chem. 285, 22532–22541 (2010).
Ruoslahti, E. Tumor penetrating peptides for improved drug delivery. Adv. Drug Deliv. Rev. 110–111, 3–12 (2017).
Jones, S. et al. Comparative lesion sequencing provides insights into tumor evolution. Proc. Natl Acad. Sci. USA 105, 4283–4288 (2008).
Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114–1117 (2010).
Meza, R., Jeon, J., Moolgavkar, S. H. & Luebeck, E. G. Age-specific incidence of cancer: phases, transitions, and biological implications. Proc. Natl Acad. Sci. USA 105, 16284–16289 (2008).
Luebeck, E. G. Cancer: genomic evolution of metastasis. Nature 467, 1053–1055 (2010).
Ittmann, M. et al. Animal models of human prostate cancer: the consensus report of the new york meeting of the mouse models of human cancers consortium prostate pathology committee. Cancer Res. 73, 2718–2736 (2013).
Puente, X. S., Sanchez, L. M., Overall, C. M. & Lopez-Otin, C. Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet. 4, 544–558 (2003).
Choi, B., Rempala, G. A. & Kim, J. K. Beyond the Michaelis–Menten equation: accurate and efficient estimation of enzyme kinetic parameters. Sci. Rep. 7, 17018 (2017).
Keu, K. V. et al. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Sci. Transl. Med. 9, eaag2196 (2017).
Widen, J. C. et al. AND-gate contrast agents for enhanced fluorescence-guided surgery. Nat. Biomed. Eng. 5, 264–277 (2021). The authors of this article show that an AND gate optical imaging probe that requires two distinct protease cleavage events significantly increased specificity and sensitivity in the detection of tumour tissue.
Ronald, J. A., D’Souza, A. L., Chuang, H. Y. & Gambhir, S. S. Artificial microRNAs as novel secreted reporters for cell monitoring in living subjects. PLoS ONE 11, e0159369 (2016).
Roybal, K. T. et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164, 770–779 (2016).
Morsut, L. et al. Engineering customized cell sensing and response behaviors using synthetic notch receptors. Cell 164, 780–791 (2016).
Holt, B. A. & Kwong, G. A. Protease circuits for processing biological information. Nat. Commun. 11, 5021 (2020).
Cazanave, S. et al. SAT-281-protease activity sensors for non-invasive monitoring of NASH. J. Hepatol. 70, e760 (2019).
Azeem, R. et al. Safety and tolerability in healthy volunteers of the Glympse bio test system-NASH diagnostic. Hepatology 72, 941A–942A (2020).
Whitley, M. J. et al. A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Sci. Transl. Med. 8, 320ra324 (2016).
Unkart, J. T. et al. Intraoperative tumor detection using a ratiometric activatable fluorescent peptide: a first-in-human phase 1 study. Ann. Surg. Oncol. 24, 3167–3173 (2017).
Smith, B. L. et al. Feasibility study of a novel protease-activated fluorescent imaging system for real-time, intraoperative detection of residual breast cancer in breast conserving surgery. Ann. Surg. Oncol. 27, 1854–1861 (2020).
Desnoyers, L. R. et al. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Sci. Transl. Med. 5, 207ra144 (2013).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT03993379 (2019).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT03013491 (2017).
Austin, R. J. et al. TriTACs, a novel class of T-cell-engaging protein constructs designed for the treatment of solid tumors. Mol. Cancer Ther. 20, 109–120 (2021).
US National Library of Medicine. ClinicalTrials.gov, https://ClinicalTrials.gov/show/NCT03577028 (2018).
Horwitz, S. et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 393, 229–240 (2019).
Duong, M. T., Qin, Y., You, S. H. & Min, J. J. Bacteria–cancer interactions: bacteria-based cancer therapy. Exp. Mol. Med. 51, 1–15 (2019).
Rozenblatt-Rosen, O. et al. The human tumor atlas network: charting tumor transitions across space and time at single-cell resolution. Cell 181, 236–249 (2020).
Rajkomar, A., Dean, J. & Kohane, I. Machine learning in medicine. N. Engl. J. Med. 380, 1347–1358 (2019). This article provides a conceptual overview of the use of machine learning and its applications in medicine.
Sidey-Gibbons, J. A. M. & Sidey-Gibbons, C. J. Machine learning in medicine: a practical introduction. BMC Med. Res. Methodol. 19, 64 (2019).
Madabhushi, A. & Lee, G. Image analysis and machine learning in digital pathology: challenges and opportunities. Med. Image Anal. 33, 170–175 (2016).
Cui, M. & Zhang, D. Y. Artificial intelligence and computational pathology. Lab. Invest. 101, 412–422 (2021).
Golub, T. R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531 (1999).
Perakakis, N., Yazdani, A., Karniadakis, G. E. & Mantzoros, C. Omics, big data and machine learning as tools to propel understanding of biological mechanisms and to discover novel diagnostics and therapeutics. Metabolism 87, A1–A9 (2018).
Grapov, D., Fahrmann, J., Wanichthanarak, K. & Khoomrung, S. Rise of deep learning for genomic, proteomic, and metabolomic data integration in precision medicine. OMICS 22, 630–636 (2018).
Douglas, G. M. et al. Multi-omics differentially classify disease state and treatment outcome in pediatric Crohn’s disease. Microbiome 6, 13 (2018).
Tasaki, S. et al. Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission. Nat. Commun. 9, 2755 (2018).
Pavel, A. B., Sonkin, D. & Reddy, A. Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activity. BMC Syst. Biol. 10, 16–16 (2016).
Breiman, L. Random forests. Mach. Learn. 45, 5–32 (2001).
van der Maaten, L. & Hinton, G. Visualizing data using t-SNE. J. Mach. Learn. Res. 9, 2579–2605 (2008).
The US National Cancer Institute organized the Synthetic Biomarkers for Detection of Cancers at Incipient and Early Stages (SYNDICATE) Think Tank Meeting in 2019, where bioengineers, biologists and clinicians discussed the promises and challenges of synthetic biomarkers from development to preclinical models to scale up to meeting the ultimate goal of safe use in the clinic. The authors express their gratitude to all SYNDICATE meeting participants for their thoughts, expertise and insightful comments. They thank T. Danino (Columbia University) and L. Chan (Georgia Tech & Emory University) for insightful discussions. This work was funded by the US NIH Director’s New Innovator Award (DP2HD091793) and the National Cancer Institute R01 grant 5R01CA237210 to G.A.K. S.N.B. is a Howard Hughes Medical Institute investigator. L.G. was supported by the US National Science Foundation Graduate Research Fellowship Program (DGE-1451512). This work was performed in part at the Georgia Tech Institute for Electronics and Nanotechnology, a member of the National Nanotechnology Coordinated Infrastructure, which is supported by the National Science Foundation (grant ECCS-1542174). This content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
G.A.K. is a co-founder of Glympse Bio, and consults for Glympse Bio and Satellite Bio. S.N.B. is a director of Vertex, is a co-founder of and consultant for Glympse Bio, Satellite Bio and CEND Therapeutics, is a consultant for Moderna, and receives sponsored research funds from Johnson & Johnson. S.G., C.P., S.S. and L.G. declare no conflicts of interest.
This article is dedicated to the late Dr Sanjiv Sam Gambhir, a visionary pioneer and thought leader in bioengineering who devoted his career to developing methods for early disease detection.
Peer review information
Nature Reviews Cancer thanks the anonymous reviewers for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Multicompartment models
A mathematical modelling technique whereby distinct compartments are used to represent organs, tissues, blood or lymph to predict how an administered drug is absorbed, distributed, metabolized or excreted.
- Hydrodynamic radius
For a macromolecule in solution, the radius of an equivalent hard sphere diffusing at the same rate as the macromolecule.
- Deuterated metabolite
A compound in which one or more hydrogen atoms have been replaced by the stable isotope deuterium to distinguish it from its unmodified counterpart.
- Bio-orthogonal reporters
Non-native reporters that do not interfere with biological functions.
- Herpes simplex virus 1 thymidine kinase
(HSV1-TK). The enzyme expressed by the reporter gene phosphorylates radiolabelled purine and pyrimidine nucleoside analogues to trap the probe within cells and thereby allow visualization by positron emission tomography (PET).
- AND gate
A Boolean logic gate operation that outputs a value of 1 if and only if both inputs are 1; otherwise it outputs 0.
About this article
Cite this article
Kwong, G.A., Ghosh, S., Gamboa, L. et al. Synthetic biomarkers: a twenty-first century path to early cancer detection. Nat Rev Cancer 21, 655–668 (2021). https://doi.org/10.1038/s41568-021-00389-3